Wednesday, July 8, 2026

pharma · Acute Schizophrenia · Schizophrenia · RVPH

REVIVA PHARMACEUTICALS HOLDINGS

REVIVA PHARMACEUTICALS HOLDINGS clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Cupertino, USA HQ
20 Employees
Public company Type
RVPH · NYSE Ticker
Company details
Status
Public
HQ
Cupertino, USA
Employees
20
Programs
3
Drugs
1
Patents
28
Intelligence · Clinical Programs

REVIVA PHARMACEUTICALS HOLDINGS projects

1 ClinicalTrials.gov programs sponsored by REVIVA PHARMACEUTICALS HOLDINGS.

REVIVA PHARMACEUTICALS HOLDINGS has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Brilaroxazine

    REVIVA PHARMACEUTICALS HOLDINGS, INC.

    Schizophrenia

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does REVIVA PHARMACEUTICALS HOLDINGS have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.